乳腺癌组织芯片 75例,150芯(1.1mm),系列8
乳腺癌组织芯片,系列8,不与BRC1501到BRC1507或BRC1509到BRC15011重复,150芯,包括正常/良性(5例)和癌(70例)组织提供分级,TNM分期,和AR,ER,PR,HER2,P53,EGFR,Ki67 IHC数据。
| CR-XBRC1508 |
| BRC1508乳腺癌,75例,150芯(1.1mm),系列8 |
| 乳腺癌组织芯片,系列8,不与BRC1501到BRC1507或BRC1509到BRC15011重复,150芯,包括正常/良性(5例)和癌(70例)组织提供分级,TNM分期,和AR,ER,PR,HER2,P53,EGFR,Ki67 IHC数据。 |
| 150芯 |
| 75例 |
| 福尔马林固定24h |
| HE染色和IHC染色 |
| 常规组织学操作包括免疫组织化学(IHC)和原位杂交(ISH),可以在我们的技术支持页面找到操作流程。 |
| 1.收到产品后请常温保存,并在24个月内使用,2.请在实验前60°烤片30分钟,3.请选择温和的修复方式,以免造成组织脱落。 |
| |
|
|
|
|
|
|
|
|
| 年龄 |
性别 |
标本部位 |
病理分类 |
病理分级 |
TNM_T |
TNM_N |
TNM_M |
|
| 45 |
F |
乳腺 |
正常 |
|
|
|
|
|
| 33 |
F |
乳腺 |
正常 |
|
|
|
|
|
| 14 |
F |
乳腺 |
纤维腺瘤 |
|
|
|
|
|
| 22 |
F |
乳腺 |
纤维腺瘤 |
|
|
|
|
|
| 18 |
F |
乳腺 |
纤维腺瘤 |
|
|
|
|
|
| 63 |
F |
乳腺 |
粘液癌 |
|
T2 |
N0 |
M0 |
|
| 42 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 50 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 42 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N1 |
M0 |
|
| 57 |
F |
乳腺 |
浸润性导管癌 |
II |
T4 |
N0 |
M0 |
|
| 42 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 39 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N0 |
M0 |
|
| 48 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 50 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 38 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N1 |
M0 |
|
| 45 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N1 |
M0 |
|
| 40 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 59 |
F |
乳腺 |
浸润性小叶癌 |
II |
T2 |
N0 |
M0 |
|
| 55 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N0 |
M0 |
|
| 49 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 39 |
F |
乳腺 |
浸润性小叶癌 |
I |
T3 |
N0 |
M0 |
|
| 75 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 66 |
F |
乳腺 |
浸润性乳头状癌 |
|
T3 |
N1 |
M0 |
|
| 60 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N1 |
M0 |
|
| 45 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 57 |
F |
乳腺 |
浸润性导管癌 |
II |
T4 |
N0 |
M0 |
|
| 46 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 78 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N1 |
M0 |
|
| 65 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N1 |
M0 |
|
| 55 |
F |
乳腺 |
浸润性小叶癌 |
II |
T3 |
N1 |
M0 |
|
| 70 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 40 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N0 |
M0 |
|
| 54 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 73 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 44 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 51 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N0 |
M0 |
|
| 39 |
F |
乳腺 |
导管原位癌 |
|
Tis |
N0 |
M0 |
|
| 37 |
F |
乳腺 |
粘液癌 |
|
T3 |
N1 |
M0 |
|
| 43 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 69 |
F |
乳腺 |
浸润性导管癌 |
II |
T4 |
N1 |
M0 |
|
| 52 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N0 |
M0 |
|
| 47 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 69 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 41 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N0 |
M0 |
|
| 37 |
F |
乳腺 |
浸润性小叶癌 |
III |
T2 |
N1 |
M0 |
|
| 60 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N0 |
M0 |
|
| 47 |
F |
乳腺 |
浸润性导管癌 |
III |
T1 |
N2 |
M0 |
|
| 74 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 31 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 47 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 47 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 57 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 52 |
F |
乳腺 |
导管原位癌 |
|
Tis |
N0 |
M0 |
|
| 62 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N1 |
M0 |
|
| 68 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 26 |
F |
乳腺 |
浸润性小管癌 |
I |
T2 |
N0 |
M0 |
|
| 43 |
F |
乳腺 |
导管原位癌 |
|
Tis |
N1 |
M0 |
|
| 35 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 38 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 48 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 53 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N0 |
M0 |
|
| 42 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 49 |
F |
乳腺 |
浸润性导管癌 |
I |
T2 |
N1 |
M0 |
|
| 55 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 62 |
F |
乳腺 |
浸润性导管癌 |
III |
T3 |
N0 |
M0 |
|
| 42 |
F |
乳腺 |
浸润性小叶癌 |
II |
T3 |
N1 |
M0 |
|
| 45 |
F |
乳腺 |
浸润性导管癌 |
II |
T4 |
N1 |
M0 |
|
| 36 |
F |
乳腺 |
浸润性导管癌 |
II |
T1 |
N1 |
M0 |
|
| 57 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| 59 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N0 |
M0 |
|
| 50 |
F |
乳腺 |
浸润性导管癌 |
II |
T4 |
N1 |
M0 |
|
| 48 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 45 |
F |
乳腺 |
浸润性导管癌 |
III |
T2 |
N0 |
M0 |
|
| 73 |
F |
乳腺 |
浸润性导管癌 |
II |
T2 |
N0 |
M0 |
|
| 61 |
F |
乳腺 |
浸润性导管癌 |
II |
T3 |
N0 |
M0 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|